Oncothyreon to receive milestone payment ( BELLEVUE WA May 14 / Oncothyreon ...)

Oncothyreon to receive milestone payment

Date:5/14/2008

BELLEVUE, WA, May 14 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) (the "Company") today announced that it has completed the transfer of certain assays and manufacturing technology related to Stimuvax(R) (BLP25 liposome vaccine) to Merck KGaA of Darmstadt, Germany, triggering a payment to Oncothyreon of $3 million. The payment will be made under the terms of the amended and restated supply agreement signed in August 2007.

Stimuvax is an investigational therapeutic cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a glycoprotein antigen widely expressed on common cancers. Merck KGaA currently is conducting a global Phase 3 trial of Stimuvax known as START (Stimulating Targeted Antigenic Responses To NSCLC). START is a randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage III NSCLC who have had a response or stable disease after at least two cycles of platinum based chemo-radiotherapy. The trial is expected to enroll more than 1,300 patients in approximately 30 countries. For more information on the START trial, or to find a participating center and eligibility criteria, log on to http://www.nsclcstudy.com or http://www.clinicaltrials.gov.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information visit http://www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and f
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Oncothyreon Reports First Quarter 2008 Financial Results
2. Oncothyreon files investigational new drug application for PX-866 oncology compound
3. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
4. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
5. Oncothyreon announces effectiveness of shelf registration statement
6. Oncothyreon announces issuance of patent for PX-867
7. Oncothyreon to present at upcoming investment conferences
8. Oncothyreon reports full year and fourth quarter 2007 financial results
9. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
10. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
11. Oncothyreon launches new corporate website

Post Your Comments:

Oncothyreon to receive milestone payment( BELLEVUE WA May 14 / Oncothyreon ...)